AdageneADAG
Recorded

Adagene 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration24 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Guggenheim, and I'm very pleased to welcome our next presenting company, Adagene, and with us is Mickael Chane-Du, Chief Strategy Officer. Michael, thanks for joining us.

Speaker

Thanks for having me. So maybe just to start, for those who are newer perhaps to the Adagene story, could you provide a quick overview of the company, your platform, and your lead asset, muzastotug, also known as ADG126?

Mickael Chane-DuChief Strategy Officer

Sure. Adagene is a company focused on protein engineering, and we are notably known to develop a We have our own proprietary fully owned masking technology, and as you mentioned, we have a lead candidate called Muza, or ADG126. I'm going to say 126 for the remainder of the chat. 126 is a mask and a masking CTLA-4. We believe that it is a very differentiated CTLA-4 and a differentiated masking antibody. We will talk more about the data, but we believe that we have expanded the therapeutic window of CTLA-4 inhibition with it.

Speaker

Great. As you mentioned, CTLA-4, proven IO target, but immune tox has always limited it to some degree.

Speaker

What was built into Muza to widen that therapeutic window, and how is it fundamentally different from first-gen antibodies like ipilimumab?

Mickael Chane-DuChief Strategy Officer

Sure. Number 1, we bind to a different epitope compared to ipilimumab, tremelimumab, or the botensilimab of the world. That differential epitope binding leads to a much stronger ADCC compared to Ipi. We believe that it is 10X higher, and this is data that has been replicated by third party, so we feel very good about mentioning that number. That's number 1. Number 2, we are using our SAFEbody, our masking technology to it. Two things about the SAFEbody technology applied to 126. A, we are protease sensitive, and we believe that our masking efficiency is best in class, which is very important. You don't want the CTLA-4 inhibitor to bind to the target when the mask is supposed to be there, and when the mask is supposed to be cleaved, you want it to bind to the target.

Mickael Chane-DuChief Strategy Officer

The whole concept about the masking efficiency is very important to us, and again, we believe that we have best-in-class masking efficiency. B, I'll mention also that we not only need certain proteases at high concentration in the tumor microenvironment to have activation and cleavage of the mask, we also need high expression of the target here, in this case, CTLA-4. So we need these two conditions for activation, which we believe participates strongly in the expansion of the therapeutic index.

Speaker

Okay. So, you reported some very meaningful phase I update this past spring for Muza plus pembro in late-line colorectal cancer patients that do not have liver metastases.

Speaker

Could you just walk us through the data you've shared to date and how that emerging clinical profile compares with the standard of care?

Mickael Chane-DuChief Strategy Officer

Sure. So I'm going to start with the safety. We have generated data for ADG126 in combination with pembrolizumab in the setting you just mentioned. Let's start with the safety. Our discontinuation rate due to adverse event is less than 10%. It's very close to what you would expect from KEYTRUDA single agent, even though we are dosing patients all the way up to 20 mg per kilogram. For people who are not aware, the first generation of CTLA-4 antibodies usually are given between one and three mg per kg. For example, when you look at ipilimumab, the fact that we're giving such a high dose without patients dropping out is very significant in our opinion. Number two, let's turn to the efficacy side, ORR, PFS, and OS.

Mickael Chane-DuChief Strategy Officer

At the relevant doses, which goes from 10 mg per kilogram Q3W all the way up to two cohorts at high dose 20 MPK, you have 20 MPK Q6W, and we have something called the loading dose, 20 followed by 10 with a schedule of Q3W. At these relevant doses, our response rate in the setting you mentioned is between 15% and 36%, and we're talking about confirmed responses. This is quite an important This is quite a substantial range, keeping in mind that single agent KEYTRUDA is known to have a response rate close to 0%, and durvalumab, tremelimumab, in the very same setting, had a response rate of 2%-3%. That's in terms of response rate.

Mickael Chane-DuChief Strategy Officer

Our median PFS is four to five months, and importantly, at the combined 10 MPK cohort, we have generated a median overall survival of close to 20 months, followed by a plateau, which you would expect from immuno-oncology agents. We believe that that kind of dataset compares very favorably versus not only KEYTRUDA single agent, the first generation CTLA-4 PD-1, but also compared to the standard of care in the same setting. Again, setting of patients without liver metastasis.

Speaker

Okay. Based on the data to some degree, you're also evaluating Muza now in a phase II study, which I think updated today has completed enrollment. Can you remind us of that study design and your line of sight into the first clinical update from the phase II?

Mickael Chane-DuChief Strategy Officer

Sure. This is a phase II that we're doing to comply with Project Optimus of the FDA. We have 60 patients randomized one-to-one between two doses. Dose number 1 is 10 milligram per kilogram every three weeks in combination with KEYTRUDA. Cohort number 2 is 20 MPK Q6W, also in combination with KEYTRUDA. Just to be clear there, we're talking about dosing schedules that are on label for KEYTRUDA. The primary endpoint of that trial is response rate, and there's a number of important secondary endpoints, safety, et cetera, duration of response, that we will be looking at. In terms of timing, you should expect data in the first half of 2027.

Mickael Chane-DuChief Strategy Officer

Again, keeping in mind that the primary endpoint of the trial is response rate, but we obviously want to have a view also on what could be duration of response, early PFS, but it will be too early to make a call on survival.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day